APA (7th ed.) Citation

P, H., AT, P., S, S., JC, V., C, M., J, K., . . . J, B. (2021). Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: The LEAVO non-inferiority three-arm RCT. Health technology assessment (Winchester, England), 25(38), 1. https://doi.org/10.3310/hta25380

Chicago Style (17th ed.) Citation

P, Hykin, et al. "Intravitreal Ranibizumab Versus Aflibercept Versus Bevacizumab for Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Non-inferiority Three-arm RCT." Health Technology Assessment (Winchester, England) 25, no. 38 (2021): 1. https://doi.org/10.3310/hta25380.

MLA (9th ed.) Citation

P, Hykin, et al. "Intravitreal Ranibizumab Versus Aflibercept Versus Bevacizumab for Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Non-inferiority Three-arm RCT." Health Technology Assessment (Winchester, England), vol. 25, no. 38, 2021, p. 1, https://doi.org/10.3310/hta25380.